H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals to $325 from $300 and keeps a Buy rating on the shares. The analyst cites the potential for Trikafta’s approval and label expansion in children 2-5 years old for the target raise.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $342 from $313 at Barclays
- Vertex Pharmaceuticals board authorizes $3.0B buyback
- Vertex Pharmaceuticals reports Q4 EPS $3.76, consensus $3.51
- Vertex options imply 3.7% move in share price post-earnings
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
